Skip to main content
. 2022 Mar 7;38(12):110561. doi: 10.1016/j.celrep.2022.110561

Figure 1.

Figure 1

Resurfacing and hyperglycosylation approaches for immune focusing

(A) Design schematics for resurfacing SARS-1 (rsSARS-1) and WIV1 (rsWIV1) scaffolds with the SARS-2 receptor binding motif (RBM) and for hyperglycosylating SARS-2 (blue), rsSARS-1 (green), and rsWIV1 (purple) receptor binding domains (RBDs). Non-native engineered glycans and native glycans are modeled; native SARS-2 RBD glycan at position 331 is omitted in the schematic. Although glycans at positions 441 and 468 technically fall within the RBM, they are on the sides of the RBD, as shown in the model. Mutations in the WIV1 and SARS-1 RBDs are shown in red and italicized in the linear diagram. All images were created using PDB: 6M0J.

(B) Design schematic for generating RBD trimers appended onto a cystine-stabilized (red stars) hyperglycosylated GCN4 tag (PDB: 6VSB).

(C) Schematic of immunization cohorts. The Trimer, Trimerhg, and Cocktailhg cohorts each contained 10 mice, and the Trivalent and RBMhg cohorts each contained 5 mice.

See also Figures S1 and S2.